June 17, 2020
AVEO Announces Pricing of $44.6 Million Public Offering of Common Stock
Aveo expects the gross proceeds from the offering to be approximately $44.6 million.
Pharmaceuticals, Biotechnology and Life Sciences
Tag: AVEO Oncology
June 15, 2020
AVEO Announces Proposed Public Offering of Common Stock
BOSTON–(BUSINESS WIRE)–AVEO Oncology (Nasdaq: AVEO) today announced that it has commenced an underwritten public offering of $40.0 million of shares…
September 30, 2019
AVEO Oncology kicks off enrolling patients in Phase 1b/2 sStudy of Fotivda plus Imfinzi previously untreated metastatic hepatocellular carcinoma
CAMBRIDGE, Mass.–(BUSINESS WIRE)–AVEO Oncology (NASDAQ: AVEO) today announced that it has initiated enrollment in an open-label, multi-center Phase 1b/2 clinical…
September 23, 2019
AVEO Oncology and EUSA Pharma Announce Presentation of Final PFS Results from Phase 2 Portion of the TiNivo Study in Renal Cell Carcinoma
– Results Suggest Additive or Synergistic Activity in Both Treatment Naïve and Previously Treated Patients – -Tivozanib-Nivolumab Combination Generally Well…